Nuveen’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Nuveen’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-73,349	Closed	-$537K	–	3659
2021 Q1	$537K	Sell	73,349 -6,919	-9%	-$59.7K	﹤0.01%	3083
2020 Q4	$463K	Buy	80,268 +18,632	+30%	+$107K	﹤0.01%	3055
2020 Q3	$366K	Buy	61,636 +27,656	+81%	+$137K	﹤0.01%	3036
2020 Q2	$175K	Buy	+33,980	New	+$214K	﹤0.01%	3119

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen's AVEO Position: Q2 2021 in Review

Nuveen sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 73,349 shares — an estimated $537K sold.

Nuveen first reported a position in AVEO in Q2 2020 and held it in 4 quarters. The position peaked at $537K in Q1 2021. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

Nuveen reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Nuveen sold 73,349 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $537K.
Nuveen first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
Nuveen's AVEO Pharmaceuticals, Inc. position peaked at $537K in Q1 2021.
63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.